OptiBiotix Health PLC Exclusive distribution agreement with MAXCARE Inc (3368M)
11 May 2020 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 3368M
OptiBiotix Health PLC
11 May 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Exclusive distribution agreement with MAXCARE Inc. for
SlimBiome(R) in Taiwan
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has
entered into a distribution agreement for SlimBiome(R) with MAXCARE
Inc ("MAXCARE"). The agreement grants MAXCARE exclusive rights to
commercialise OptiBiotix's SlimBiome(R) proprietary weight
management technology in Taiwan.
MAXCARE ( https://www.maxcarecorp.com ) is a Taiwanese company
based in Taipei founded in 2000 which specialises in
clinically-supported, science based nutraceuticals, fruit and
botanical extracts. MAXCARE's ingredients span a wide range of
application areas with an existing distribution network and
experience in commercialising weight management ingredients. Market
exclusivity is linked to minimum sales targets being achieved.
MAXCARE is one of Taiwan's leading distributors for
nutraceutical raw materials which offers a complete portfolio of
products, technological development support and logistical
services. Their distribution channels include TV shopping, chain
pharmacies, drug stores and direct/multi-layer selling. They are
well placed to educate customers on the benefits and functionality
SlimBiome(R) can provide and have a team of registered dieticians
to support commercialisation.
This is another strategic step by OptiBiotix to commercilise its
award-winning SlimBiome(R) technology into new markets. The
commercial aim is to develop SlimBiome(R) as an innovative
ingredient that can be added to multiple products in different
application areas incorporating science backed functionality and
additional value to everyday products.
Thomas O'Hara, Business Development Manager at Optibiotix , c o
mmented: "We are pleased to have signed an agreement with MAXCARE
to commercialise our award-winning weight management technology in
Taiwan. We chose MAXCARE due to their experience in commercialising
weight management ingredients and their understanding of the value
proposition SlimBiome(R) provides to their customers. Having a
trained team of registered dieticians that can provide technical
support allows them to clearly convey the benefits and value
SlimBiome(R) can add to a range of products.
"MAXCARE has placed an initial trial order on signing the
agreement as a result of early interest received from introducing
SlimBiome(R) to their customers. We look forward to continuing the
current trajectory of SlimBiome(R) and increasing the countries,
applications, products, revenues and overall global brand value in
the months and years ahead."
Steve Wu, General Manager at MAXCARE Inc , c o mmented: "The
weight management market constitutes circa USD$2 billion value in
Taiwan each year (Source: Functional Food Status Report 2018).
Besides the traditional sales channels, an increasing number of
weight loss clinics has also greatly driven its growth. There are
abundant products that target weight loss on the market, yet very
few have scientifically and clinically proven efficacies, with no
side effects. SlimBiome (R) of OptiBiotix is a patented product,
with clinical proof to improve gut microbiome, support weight lost,
stabilise blood sugar and reduce cravings for food, which all lead
to successful weight management. It has always been our goal to
partner with companies that are capable of producing such products.
MAXCARE represents a large number f nutraceutical ingredients with
clinical studies, manufactured by pharmaceutical and/or major food
manufacturers, and it is our great pleasure to be working with
Optibiotix for the distribution of SlimBiome (R) in Taiwan. We are
very optimistic about the prospects of SlimBiome(R) in this region
and look forward to working with the OptiBiotix team to maximise
the potential."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBLGDUDBGDGGR
(END) Dow Jones Newswires
May 11, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
